Skip to main content
Home

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Home

Main navigation InfoLep

  • Leprosy [5]
    • Global and Regional Leprosy Situation
    • WHO Global Leprosy Strategy
    • ILEP Strategy
    • World Leprosy Day
    • Leprosy journals
  • Key topics [7]
    • Leprosy and COVID-19
    • Diagnostic tests
    • Prevention of leprosy [2]
      • Interventions to reduce transmission: post-exposure prophylaxis (PEP) [3]
        • LPEP Programme
        • PEP++ project
        • PEP4LEP project
      • Interventions to reduce transmission: vaccines
    • Rehabilitation & prevention of disability [2]
      • Preventing leprosy-related disabilities in girls and boys
      • Self-care in leprosy
    • Leprosy Antibiotic Treatment
    • Stigma, discrimination & mental wellbeing [4]
      • World Leprosy Day 2022
      • Gender
      • Mental wellbeing
      • SARI Project
    • Bioarchaeology of leprosy
  • Toolkits [6]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • Perception Study Toolkit (PST)
    • Zero Leprosy Toolkit
    • CBM's Community Mental Health Good Practice Guides
    • GPZL & Infolep Factsheets
  • Online courses
  • Ocular DB

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Visit our e-learning platform
Search resources Search in Practical Materials, Publications, Organizations, Online Course and more
Publication

Immunohistochemical Characterization of M1, M2, and M4 Macrophages in Leprosy Skin Lesions

Quaresma TC, de Aguiar Valentim L, de Sousa JR, et al. MDPI AG. Pathogens. 2023; 12 (10) : 1-14.
Download PDF
Publication

Intra-urban differences underlying leprosy spatial distribution in central Brazil: geospatial techniques as potential tools for surveillance

Carvalho AG, Dias CLH, Blok DJ, et al. PAGEPress Publications. Geospatial Health. 2023;
Download PDF
Publication

To study the effectiveness of Methotrexate as a steroid sparing agent in Type 2 Lepra reaction

Batham M, Malviya A, Kumar V, et al. Journal of Cardiovascular Disease Research. 2023; 14 (9) : 620-624.
Download PDF
Publication

Clitoria Ternatea Antioxidant Reduces Serum MDA in Leprosy Patients with Reversal Reactions

Ananda FA, Kusumaningrum N, Muniroh M, et al. LPPM Akper Yapenas 21 Maros. Jurnal Ilmiah Kesehatan (JIKA). 2023; 5 (2) : 291-301.
Download PDF
Publication

Leprosy Neuropathy: Clinical Presentation

Noer R. R, Kurniawan S. N. Journal of Pain, Headache, and Vertigo. 2023; 4 (2) : 27-30.
Download PDF
Publication

Use of Multidrug Therapy Regimen for Hansen Disease Patients

Nawaz S. Mycobacterial Diseases. 2023; 13 (5) : 1.
Download PDF
Publication

Multiplex PCR-based RFLP assay for early identification of prevalent Mycobacterium leprae genotypes.

Dwivedi P, Sharma M, Singh P. Diagnostic microbiology and infectious disease. 2023;
Publication

Specialized active leprosy search strategies in an endemic area of the Brazilian Amazon identifies a hypermutated strain causing primary drug resistance.

Bouth R, Gobbo A, Barreto J, et al. Frontiers in medicine. 2023;
Download PDF
Publication

Vision-related quality of life among released from treatment cases of leprosy evaluated with NEI-VFQ-25: a cross-sectional study.

Irawati Y, Andayani G, Rahayu T, et al. BMC ophthalmology. 2023; 23 (1) : 1-8.
Download PDF
Publication

Are leprosy and Hansen's disease identical?

Guo J, Dong X. Nature. 2023; 622 (7981) : 31.

Pagination

  • Previous page ‹‹
  • Page 163
  • Next page ››
Subscribe to Leprosy (Hansen disease)

Quick links

  • Leprosy
  • Key topics
  • Toolbox
  • Publications

Support

  • Contact
  • Privacy statement
  • Contact
  • FAQ

Contact us

info@infolep.org

(+31) 20 595 0500

     

Stay up to date with the latest publications and news related to leprosy.

Subscribe to newsletter

Related websites:

© 2025 InfoNTD